在小鼠中建立膀胱癌模型：机遇与挑战。
Modelling bladder cancer in mice: opportunities and challenges.
作者信息
Kobayashi Takashi, Owczarek Tomasz B, McKiernan James M, Abate-Shen Cory
机构信息
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
1] Department of Urology, Columbia University Medical Center. [2] Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032, USA.
出版信息
Nat Rev Cancer. 2015 Jan;15(1):42-54. doi: 10.1038/nrc3858.
Abstract
The prognosis and treatment of bladder cancer have improved little in the past 20 years. Bladder cancer remains a debilitating and often fatal disease, and is among the most costly cancers to treat. The generation of informative mouse models has the potential to improve our understanding of bladder cancer progression, as well as to affect its diagnosis and treatment. However, relatively few mouse models of bladder cancer have been described, and in particular, few that develop invasive cancer phenotypes. This Review focuses on opportunities for improving the landscape of mouse models of bladder cancer.
摘要
在过去20年里，膀胱癌的预后和治疗进展甚微。膀胱癌仍然是一种使人衰弱且往往致命的疾病，也是治疗成本最高的癌症之一。构建信息丰富的小鼠模型有潜力增进我们对膀胱癌进展的理解，并影响其诊断和治疗。然而，已描述的膀胱癌小鼠模型相对较少，尤其是很少有能产生浸润性癌表型的模型。本综述着重探讨改善膀胱癌小鼠模型现状的机会。
相似文献
1
Modelling bladder cancer in mice: opportunities and challenges.在小鼠中建立膀胱癌模型：机遇与挑战。
Nat Rev Cancer. 2015 Jan;15(1):42-54. doi: 10.1038/nrc3858.
2
Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.犬浸润性移行细胞癌细胞系：用于补充浸润性膀胱癌相关动物模型的体外工具。
Urol Oncol. 2009 May-Jun;27(3):284-92. doi: 10.1016/j.urolonc.2008.02.015. Epub 2008 Jun 18.
3
Mouse orthotopic models for bladder cancer research.用于膀胱癌研究的小鼠原位模型。
BJU Int. 2009 Nov;104(9):1286-91. doi: 10.1111/j.1464-410X.2009.08577.x. Epub 2009 Apr 16.
4
EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.乙二胺四乙酸诱导的尿路上皮细胞脱落用于治疗小鼠浅表性膀胱癌
Int J Urol. 2006 Oct;13(10):1344-6. doi: 10.1111/j.1442-2042.2006.01541.x.
5
Bladder cancer today.
BJU Int. 2008 Nov;102(9 Pt B):1203. doi: 10.1111/j.1464-410X.2008.08159.x.
6
[Animal models of bladder cancer].[膀胱癌动物模型]
Hinyokika Kiyo. 1988 Nov;34(11):1923-7.
7
Bladder cancer: a disease ripe for major advances.膀胱癌：一种亟待取得重大进展的疾病。
Clin Adv Hematol Oncol. 2014 Dec;12(12):838-45.
8
Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives.膀胱癌干细胞样细胞：其起源与治疗前景
Int J Mol Sci. 2015 Dec 29;17(1):43. doi: 10.3390/ijms17010043.
9
Roles of HIF-1α in a novel optical orthotopic spontaneous metastatic bladder cancer animal model.缺氧诱导因子-1α 在新型光学原位自发性转移性膀胱癌动物模型中的作用。
Urol Oncol. 2012 Nov-Dec;30(6):928-35. doi: 10.1016/j.urolonc.2012.01.003. Epub 2012 Feb 14.
10
The costs of non-muscle invasive bladder cancer.非肌肉浸润性膀胱癌的成本。
Urol Clin North Am. 2013 May;40(2):261-9. doi: 10.1016/j.ucl.2013.01.004. Epub 2013 Feb 13.
引用本文的文献
1
Intravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In Murine Model.用于小鼠模型有效化疗的膀胱内肿瘤选择性粘膜粘附水凝胶
Int J Nanomedicine. 2025 Jun 4;20:7169-7183. doi: 10.2147/IJN.S522421. eCollection 2025.
2
Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma.犬浸润性尿路上皮癌中罕见组织学亚型的频率及特征
bioRxiv. 2025 May 14:2025.05.13.651218. doi: 10.1101/2025.05.13.651218.
3
PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations.在一个携带p53错义突变的新型尿路上皮类器官模型中，PTEN缺失导致p53杂合性缺失和免疫逃逸。
Oncogene. 2025 May;44(19):1336-1349. doi: 10.1038/s41388-025-03311-5. Epub 2025 Feb 22.
4
A novel mouse model of upper tract urothelial carcinoma highlights the impact of dietary intervention on gut microbiota and carcinogenesis prevention despite carcinogen exposure.一种新型的上尿路尿路上皮癌小鼠模型突出了饮食干预对肠道微生物群的影响以及尽管暴露于致癌物仍能预防癌症发生。
Int J Cancer. 2025 Apr 1;156(7):1439-1456. doi: 10.1002/ijc.35295. Epub 2024 Dec 18.
5
Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms.膀胱内给药策略：基于膀胱生理屏障和潜在转运机制
Acta Pharm Sin B. 2024 Nov;14(11):4738-4755. doi: 10.1016/j.apsb.2024.07.003. Epub 2024 Jul 6.
6
YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation.YAP1通过IL-6/STAT3途径和CXCL失调诱导膀胱癌进展并促进免疫逃逸。
J Clin Invest. 2024 Dec 4;135(2):e171164. doi: 10.1172/JCI171164.
7
Loss of NUMB drives aggressive bladder cancer via a RHOA/ROCK/YAP signaling axis.NUMB缺失通过RHOA/ROCK/YAP信号轴驱动侵袭性膀胱癌。
Nat Commun. 2024 Dec 3;15(1):10378. doi: 10.1038/s41467-024-54246-6.
8
Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation.利用体内电穿孔技术开发新型免疫功能正常的膀胱癌小鼠肿瘤模型。
Sci Rep. 2024 Oct 27;14(1):25619. doi: 10.1038/s41598-024-77178-z.
9
Full-course NIR-II imaging-navigated fractionated photodynamic therapy of bladder tumours with X-ray-activated nanotransducers.全疗程近红外二区成像导航的膀胱癌分割光动力治疗，联合 X 射线激活的纳米转导剂。
Nat Commun. 2024 Sep 19;15(1):8240. doi: 10.1038/s41467-024-52607-9.
10
SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.鞘氨醇激酶1通过PD-L2/c-Src/粘着斑激酶信号级联促进膀胱癌转移。
Cell Death Dis. 2024 Sep 16;15(9):678. doi: 10.1038/s41419-024-07044-3.
本文引用的文献
1
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.肌肉浸润性膀胱癌新辅助化疗的多中心评估
Eur Urol. 2015 Feb;67(2):241-9. doi: 10.1016/j.eururo.2014.09.007. Epub 2014 Sep 23.
2
In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.Rb-E2F-Ezh2信号通路环的体内破坏会导致膀胱癌。
Cancer Res. 2014 Nov 15;74(22):6565-6577. doi: 10.1158/0008-5472.CAN-14-1218. Epub 2014 Sep 24.
3
Bladder cancers arise from distinct urothelial sub-populations.膀胱癌起源于不同的尿路上皮亚群。
Nat Cell Biol. 2014 Oct;16(10):982-91, 1-5. doi: 10.1038/ncb3038. Epub 2014 Sep 14.
4
A new tumor suppressor role for the Notch pathway in bladder cancer.Notch 通路在膀胱癌中作为一种新的肿瘤抑制因子。
Nat Med. 2014 Oct;20(10):1199-205. doi: 10.1038/nm.3678. Epub 2014 Sep 7.
5
Current animal models of bladder cancer: Awareness of translatability (Review).当前膀胱癌动物模型：对可转化性的认识（综述）
Exp Ther Med. 2014 Sep;8(3):691-699. doi: 10.3892/etm.2014.1837. Epub 2014 Jul 11.
6
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.表皮生长因子受体（EGFR）作为基底样表型的肌层浸润性膀胱癌亚组的潜在治疗靶点。
Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970.
7
Identification of potential bladder progenitor cells in the trigone.膀胱三角区潜在膀胱祖细胞的鉴定。
Dev Biol. 2014 Sep 1;393(1):84-92. doi: 10.1016/j.ydbio.2014.06.018. Epub 2014 Jun 30.
8
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.肌层浸润性膀胱癌的固有基底和腔型亚型。
Nat Rev Urol. 2014 Jul;11(7):400-10. doi: 10.1038/nrurol.2014.129. Epub 2014 Jun 24.
9
Mutational context and diverse clonal development in early and late bladder cancer.早期和晚期膀胱癌的突变背景与多样的克隆发育
Cell Rep. 2014 Jun 12;7(5):1649-1663. doi: 10.1016/j.celrep.2014.04.038. Epub 2014 May 15.
10
A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration.小鼠膀胱尿路上皮基底层和中间层中的一群祖细胞有助于尿路上皮的发育和再生。
Dev Dyn. 2014 Aug;243(8):988-98. doi: 10.1002/dvdy.24143. Epub 2014 May 19.
Zotero 插件